큐리언트

115180KOSDAQ자연과학 및 공학 연구개발업

44.8 / 100

Reference Date: 2026-07-24

Financial Score7.5 / 40

News Sentiment21.3 / 25

Momentum6.0 / 20

Disclosure10.0 / 15

AI Analysis: the high debt ratio poses financial risk, PBR raises overvaluation concerns. Plunged 18.3% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Curient is a biotech company specializing in new drug development, established with government and international investments to advance Korea's pharmaceutical and biotech industry. Collaborating with institutions like the French Pasteur Institute and Germany's Max Planck Society, it focuses on infectious disease and oncology/immunology therapies. Partnering with MSD, it develops combination therapies with Keytruda, and reported consolidated sales of 92 billion KRW in 2024.

Number of Employees

32people

Average Salary

141.8M KRW

Score Calculation Basis

Detailed Financial Score

PER

—Industry Average 43.644.0Point

PBR

17.71Industry Average 2.520.0Point

7.0x industry avg (risky)

ROE

-68.05Industry Average -32.093.5Point

2.1x industry avg (excellent)

Debt Ratio

48.23Industry Average 7.310.0Point

6.6x industry avg (risky)

Trend 2023~20250.0 / 10 points

Revenue Growth Rate

0.0 / 3

Avg ▼11.2% (2-year basis)

Operating Profit Growth Rate

0.0 / 3

Avg ▼13.3% (2-year basis)

ROE Trend

0.0 / 4

Avg ROE -57.4% (declining, 3yr)

Detailed News Sentiment

8 totalPositive 8Neutral 0Negative 0Average Sentiment Score 85

Positive
큐리언트 "美학회서 ADC 비임상 데이터 공개"
큐리언트의 HER2 표적 ADC 치료제 QP101의 긍정적인 비임상 데이터 공개로 인해 주가 상승 기대.
Positive
큐리언트, HER2 이중 페이로드 ADC 'QP101' 비임상 데이터 ...
큐리언트의 HER2 표적 ADC QP101이 AACR D3 2026에서 긍정적인 비임상 데이터를 공개하며 신약 개발에 대한 기대감을 높였다.
Positive
큐리언트, 이중 페이로드 ADC 비임상…엔허투 대비 반응률 우위
큐리언트의 QP101 ADC가 HER2 표적 임상 시험에서 우수한 안전성과 높은 반응률을 보여주며 긍정적인 비임상 결과 발표.

Detailed Momentum

52-week position3.0Point

52w lower range (20%)

Current 18,500Won52-week high 50,90052-week low 9,950

1-month return0.0Point

1m -18.32% (strong drop)

Volume trend3.0Point

Volume flat

Detailed Disclosure

0 totalPositive 0Neutral 0Negative 0